Wall Street brokerages expect Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to report earnings per share of $0.12 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is $0.23 and the lowest is $0.08. Catalyst Pharmaceuticals posted earnings of ($0.14) per share in the same quarter last year, which would suggest a positive year over year growth rate of 185.7%. The business is expected to report its next earnings results on Monday, March 16th.
On average, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of $0.37 per share for the current year, with EPS estimates ranging from $0.31 to $0.49. For the next financial year, analysts forecast that the company will report earnings of $0.52 per share, with EPS estimates ranging from $0.35 to $0.68. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $30.90 million during the quarter, compared to analyst estimates of $33.19 million. Catalyst Pharmaceuticals had a net margin of 12.99% and a return on equity of 15.53%.
Shares of NASDAQ CPRX traded up $0.15 during midday trading on Friday, hitting $4.71. The stock had a trading volume of 471,980 shares, compared to its average volume of 2,354,569. The business’s 50 day moving average is $4.89 and its 200-day moving average is $4.79. Catalyst Pharmaceuticals has a 52 week low of $1.85 and a 52 week high of $7.67. The company has a quick ratio of 5.00, a current ratio of 5.04 and a debt-to-equity ratio of 0.01. The company has a market cap of $482.27 million, a P/E ratio of -14.27 and a beta of 2.38.
In related news, CEO Patrick J. Mcenany bought 10,000 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was acquired at an average cost of $4.89 per share, for a total transaction of $48,900.00. Following the purchase, the chief executive officer now owns 4,772,693 shares in the company, valued at $23,338,468.77. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 100,000 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $4.50, for a total transaction of $450,000.00. Following the sale, the insider now owns 100,000 shares of the company’s stock, valued at $450,000. The disclosure for this sale can be found here. 10.70% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in CPRX. Tower Research Capital LLC TRC bought a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth $27,000. Meeder Asset Management Inc. increased its position in Catalyst Pharmaceuticals by 678.1% during the second quarter. Meeder Asset Management Inc. now owns 13,251 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 11,548 shares during the last quarter. Bank of Montreal Can lifted its holdings in Catalyst Pharmaceuticals by 159.1% in the second quarter. Bank of Montreal Can now owns 12,953 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 7,953 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Catalyst Pharmaceuticals in the second quarter valued at about $55,000. Finally, Paradigm Capital Management Inc. NY bought a new position in Catalyst Pharmaceuticals in the second quarter valued at about $77,000. Hedge funds and other institutional investors own 59.80% of the company’s stock.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Read More: Preferred Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.